Fig. 2.
Fig. 2. (A) Survival for T-LIN patients by the number of T-cell markers expressed. Patients expressing 6-7 markers (n = 14) had longer survival than those patients expressing 3 or fewer markers (n = 10; adjusted P = .004). Patients expressing 4-5 markers (n = 20) had intermediate survival that was not significantly different from the 6-7 marker group (adjustedP = .24) or the 1-3 marker group (adjustedP = .13). (B) DFS for T-LIN patients by the number of T-cell markers expressed. Patients expressing 6-7 markers (n = 14) had longer DFS than those patients expressing 3 or fewer markers (n = 6; adjusted P = .003). Patients expressing 4-5 markers (n = 18) have intermediate DFS that was not significantly different from the 6-7 marker group (adjusted P = .31) or the 1-3 marker group (adjusted P = .13).

(A) Survival for T-LIN patients by the number of T-cell markers expressed. Patients expressing 6-7 markers (n = 14) had longer survival than those patients expressing 3 or fewer markers (n = 10; adjusted P = .004). Patients expressing 4-5 markers (n = 20) had intermediate survival that was not significantly different from the 6-7 marker group (adjustedP = .24) or the 1-3 marker group (adjustedP = .13). (B) DFS for T-LIN patients by the number of T-cell markers expressed. Patients expressing 6-7 markers (n = 14) had longer DFS than those patients expressing 3 or fewer markers (n = 6; adjusted P = .003). Patients expressing 4-5 markers (n = 18) have intermediate DFS that was not significantly different from the 6-7 marker group (adjusted P = .31) or the 1-3 marker group (adjusted P = .13).

Close Modal

or Create an Account

Close Modal
Close Modal